These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26974759)

  • 1. Cutaneous Pseudolymphoma in a Patient With Crohn's Disease Under Infliximab: First Report.
    Carvalhana S; Gonçalves A; Velosa J
    J Clin Gastroenterol; 2016; 50(5):436-7. PubMed ID: 26974759
    [No Abstract]   [Full Text] [Related]  

  • 2. Asymptomatic Parasitic Infection in a Crohn's Disease Patient on Anti-TNFα Therapy: An Alert for Our Patients?
    Cocca S; Guarino M; Cicala M
    J Crohns Colitis; 2016 Dec; 10(12):1455-1456. PubMed ID: 27208388
    [No Abstract]   [Full Text] [Related]  

  • 3. An Unusual Cause of Skin Rash in Crohn's Disease.
    Chebli JMF; de Oliveira Moreira B; da Rocha Ribeiro TC
    Gastroenterology; 2018 Sep; 155(3):618-620. PubMed ID: 29409941
    [No Abstract]   [Full Text] [Related]  

  • 4. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab.
    Martínez F; Nos P; Benlloch S; Ponce J
    Inflamm Bowel Dis; 2001 Nov; 7(4):323-6. PubMed ID: 11720323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.
    Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG
    Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab-induced follicular mucinosis of the face.
    Williams RF; Hoang MP; Kroshinsky D; Smith GP
    Int J Dermatol; 2017 Feb; 56(2):215-217. PubMed ID: 27336710
    [No Abstract]   [Full Text] [Related]  

  • 7. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
    Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
    J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab-induced acne: report of a third case.
    Sladden MJ; Clarke PJ; Mitchell B
    Br J Dermatol; 2008 Jan; 158(1):172. PubMed ID: 17854357
    [No Abstract]   [Full Text] [Related]  

  • 9. Induction of pustular lesions during infliximab therapy for Crohn's disease.
    Pérez-Pérez L; Caeiro JL; Fabeiro JM; Allegue F; Zulaica A
    Acta Derm Venereol; 2008; 88(3):292-3. PubMed ID: 18480940
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute Tubulointerstitial Nephritis Associated with Infliximab in a Patient with Crohn's Disease.
    Ota M; Iwai H; Imai K; Kamiya M; Yoshihashi-Nakazato Y; Miyasaka N; Kohsaka H
    Intern Med; 2016; 55(10):1367-70. PubMed ID: 27181549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PANTS extension study: how best to use anti-TNF drugs in Crohn's disease.
    Parkes GC; Hedin CRH
    Lancet Gastroenterol Hepatol; 2024 Jun; 9(6):489-491. PubMed ID: 38640938
    [No Abstract]   [Full Text] [Related]  

  • 12. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypersensitivity perimyocarditis after the first dose of infliximab.
    Lezcano-Gort LE; Gómez-Barrado JJ; Mogollón-Jiménez MV; Garcipérez-de-Vargas-Díaz FJ
    Rev Esp Enferm Dig; 2015 Apr; 107(4):249. PubMed ID: 25824933
    [No Abstract]   [Full Text] [Related]  

  • 15. Psoriasiform and pustular eruption induced by infliximab.
    Takahashi H; Hashimoto Y; Ishida-Yamamoto A; Ashida T; Kohgo Y; Iizuka H
    J Dermatol; 2007 Jul; 34(7):468-72. PubMed ID: 17584325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease.
    Hirten R; Longman RS; Bosworth BP; Steinlauf A; Scherl E
    Am J Gastroenterol; 2015 Dec; 110(12):1737-8. PubMed ID: 26673509
    [No Abstract]   [Full Text] [Related]  

  • 17. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy.
    Duron C; Goutte M; Pereira B; Bommelaer G; Buisson A
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):705-11. PubMed ID: 25856689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal: An unusual opportunistic infection mimicking lymphoma in a patient receiving Infliximab for Crohn's disease.
    Ma MX; Parry J; Venugopal K; Jennings M
    J Gastroenterol Hepatol; 2017 Jun; 32(6):1131. PubMed ID: 28557200
    [No Abstract]   [Full Text] [Related]  

  • 19. Case of psoriasiform and pustular eruptions in addition to alopecia as a paradoxical reaction induced by infliximab.
    Shimokata M; Namiki T; Tokoro S; Ugajin T; Miura K; Yokozeki H
    J Dermatol; 2018 Dec; 45(12):e331-e333. PubMed ID: 29855072
    [No Abstract]   [Full Text] [Related]  

  • 20. Solitary facial cutaneous chronic inflammatory lesions induced by anti-tumour necrosis factor-α antagonist.
    Haro-Gabaldón V; Ruiz Molina I; Haro-González-Vico V; Solís García E
    Clin Exp Dermatol; 2019 Jan; 44(1):80-82. PubMed ID: 30255515
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.